Sex differences in lopinavir and ritonavir pharmacokinetics among HIV-infected women and men

Journal of Clinical Pharmacology

Volumn 51, Issue 12, 2011, Pages 1665-1673

  Umeh, Obi C ^a,e   Currier, Judith S ^a   Park, Jeong Gun ^b   Cramer, Yoninah ^b   Hermes, Ashwaq E ^c   Fletcher, Courtney V ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c ABBOTT LABORATORIES   (United States)

^d UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

^e CUBIST PHARMACEUTICALS INC   (United States)

Author keywords

HIV infection; lopinavir ritonavir; pharmacokinetics; sex differences

Indexed keywords

LOPINAVIR; LOPINAVIR PLUS RITONAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR DISOPROXIL;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG FORMULATION; ETHNICITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHARMACOKINETICS; RACE; SEX DIFFERENCE; TABLET;

ADOLESCENT; ADULT; AREA UNDER CURVE; CAPSULES; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LOPINAVIR; MALE; MIDDLE AGED; RITONAVIR; SEX FACTORS; TABLETS; YOUNG ADULT;

EID: 79959216019     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010388650     Document Type: Article

References (25)

1. Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO). AIDS Epidemic Update. http://data.unaids.org/pub/Report/ 2009/JC1700-Epi-Update-2009-en.pdf. Accessed March 29, 2010.
2. Anderson PL, Kakuda TN, Kawle S, Fletcher CV. Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals. AIDS. 2003 ; 17 (15). 2159-2168 (Pubitemid 37338889)
3. Bersoff-Matcha SJ, Miller WC, Aberg JA, et al. Sex differences in nevirapine rash. Clin Infect Dis. 2001 ; 32 (1). 124-129 (Pubitemid 32150957)
4. Burger DM, van der Heiden I, La Porte CJL, et al. Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor: efavirenz: the effect of gender, age, race, and CYP2B6 polymorphism. Br J Clin Pharmacol. 2006 ; 61 (2). 148-154 (Pubitemid 43382608)
5. van de Leur MR, Burger DM, La Porte CJ, Koopmans PP. A retrospective TDM database analysis of interpatient variability in the pharmacokinetics of lopinavir in HIV-infected adults. Ther Drug Monit. 2006 ; 28 (5). 650-653 (Pubitemid 44564064)
6. Burger DM, Siebers MC, Hugen PW, Aamoutse RE, Hekster YA, Koopmans PP. Pharmacokinetic variability caused by gender: do women have higher indinavir exposure than men?. J Acquir Immune Defic Syndr. 2002 ; 29 (1). 101-102 (Pubitemid 34094314)
7. Fletcher CV, Jiang H, Brundage RC, et al. Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359. J Infect Dis. 2004 ; 189 (7). 1176-1184 (Pubitemid 38457241)
8. Gibaldi M, Perrier D Pharmacokinetics. 2 nd ed.New York: Marcel Dekker; 1982. New York: Marcel Dekker ; 1982 :
9. US Food and Drug Administration. Guidance for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. March2003. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM070246.pdf.
10. Bertz R, Lam W, Hsu A, Granneman GR, Sun E. Effects of gender, race, age and weight on the pharmacokinetics of lopinavir (lopinavir/ritonavir) in healthy adult subjects after single-dose kaletra. Presented at: Second International Workshop on Clinical Pharmacology of HIV Therapy ; Noordwijk, Netherlands ;..
11. Ofotokun I, Chuck SK, Binongo JN, Palau M, Lennox JL, Acosta EP. Lopinavir/ritonavir pharmacokinetic profile: impact of sex and other covariates following a change from twice-daily to once-daily therapy. J Clin Pharmacol. 2007 ; 47 (8). 970-977 (Pubitemid 47094097)
12. van der Leur MR, Burger DM, la Porte CJL, Koopmans PP. A retrospective TDM database analysis of interpatient variability in the pharmacokinetics of lopinavir in HIV-infected adults. Ther Drug Monit. 2006 ; 28 (5). 650-653 (Pubitemid 44564064)
13. Breilh DH, Rouzes A, Djabarouti S, Pellegrin I, Xuereb F, Coupet AC. Pharmacokinetic drug interaction of lopinavir/ritonavir in combination with tenofovir in experienced HIV positive patients. Presented at: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy ; Washington DC ;..
14. Kearney BP, Mathias A, Mittan A, Sayre J, Ebrahimi R, Cheng AK. Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir. J Acquir Immune Defic Syndr. 2006 ; 43 (3). 278-283 (Pubitemid 44674007)
15. Johnson MA, Gathe JC, Podzamczer D, et al. A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen. J Acquir Immune Defic Syndr. 2006 ; 43 (2). 153-160 (Pubitemid 44454808)
16. Klein C, Ng J, Diderichsen PM, de Silva B, Bernstein B, Awni W. Population pharmacokinetic/pharmacodynamic analyses of lopinavir and ritonavir in subjects receiving the tablet formulation. Presented at: HIV 9 ; Glasgow, UK ;..
17. Ng J, Noertersheuser PA, Mensing S, Awni WA, Klein CE. Population pharmacokinetic analysis of lopinavir and ritonavir in HIV-1-treatment experienced subjects receiving the lopinavir/ritonavir tablet formulation. Presented at: 12th European AIDS Conference ; Cologne, Germany ;..
18. Sekar V, Ryan R, Schaible D, Mazikewich A, Mrus J. Pharmacokinetic profile of darunavir (DRV) co-administered with low dose ritonavir in treatment experienced women and men: 4 week analysis in a substudy of the GRACE trial. Presented at: 9th International Workshop on Clinical Pharmacology of HIV Therapy (IWCPHIV ; New Orleans, LA ;..
19. Gleiter CH, Gundert-Remy U. Gender differences in pharmacokinetics. Eur J Drug Metab Pharmacokinet. 1996 ; 21 (2). 123-128 (Pubitemid 26246155)
20. Harris RZ, Benet LZ, Schwartz JB. Gender effects in pharmacokinetics and pharmacodynamics. Drugs. 1995 ; 50 (2). 222-239
21. Tanaka E. Gender-related differences in pharmacokinetics and their clinical significance. J Clin Pharm Ther. 1999 1999 ; 24 (5). 339-346 (Pubitemid 29520783)
22. Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O'Mara EM, Hall SD. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther. 1998 ; 64: 133-143 (Pubitemid 28423848)
23. Kates RE, Keefe DL, Schwartz J, Harapat S, Kirsten EB, Harrison DC. Verapamil disposition kinetics in chronic atrial fibrillation. Clin Pharmacol Ther. 1981 ; 30: 44-51 (Pubitemid 11033787)
24. Krecic-Shepard ME, Barnas CR, Slimko J, Jones MP, Schwartz JB. Gender-specific effects on verapamil pharmacokinetics and pharmacodynamics in humans. J Clin Pharmacol. 2000 ; 40: 219-230
25. Klein CE, Chiu YL, Awni WA, et al. The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft gelatin capsule formulation with less pharmacokinetic variability and diminished food effect. J Acquir Immune Defic Syndr. 2007 ; 44: 401-410 (Pubitemid 46555374)